| Literature DB >> 27698489 |
Hiroki Tanigawa1,2, Keishi Miyata1,3, Zhe Tian1, Jun Aoi2, Tsuyoshi Kadomatsu1, Satoshi Fukushima2, Aki Ogata2, Naoki Takeda4, Jiabin Zhao1, Shunshun Zhu1, Kazutoyo Terada1, Motoyoshi Endo1, Jun Morinaga1, Taichi Sugizaki1, Michio Sato1, Masaki Suimye Morioka5, Ichiro Manabe5, Youichi Mashimo6, Akira Hata6, Yoshitaka Taketomi7, Kei Yamamoto7,8, Makoto Murakami7, Kimi Araki4, Masatoshi Jinnin2, Hironobu Ihn2, Yuichi Oike1.
Abstract
Psoriasis is a chronic inflammatory skin disease marked by aberrant tissue repair. Mutant mice modeling psoriasis skin characteristics have provided useful information relevant to molecular mechanisms and could serve to evaluate therapeutic strategies. Here, we found that epidermal ANGPTL6 expression was markedly induced during tissue repair in mice. Analysis of mice overexpressing ANGPTL6 in keratinocytes (K14-Angptl6 Tg mice) revealed that epidermal ANGPTL6 activity promotes aberrant epidermal barrier function due to hyperproliferation of prematurely differentiated keratinocytes. Moreover, skin tissues of K14-Angptl6 Tg mice showed aberrantly activated skin tissue inflammation seen in psoriasis. Levels of the proteins S100A9, recently proposed as therapeutic targets for psoriasis, also increased in skin tissue of K14-Angptl6 Tg mice, but psoriasis-like inflammatory phenotypes in those mice were not rescued by S100A9 deletion. This finding suggests that decreasing S100A9 levels may not ameliorate all cases of psoriasis and that diverse mechanisms underlie the condition. Finally, we observed enhanced levels of epidermal ANGPTL6 in tissue specimens from some psoriasis patients. We conclude that the K14-Angptl6 Tg mouse is useful to investigate psoriasis pathogenesis and for preclinical testing of new therapeutics. Our study also suggests that ANGPTL6 activation in keratinocytes enhances psoriasis susceptibility.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27698489 PMCID: PMC5048131 DOI: 10.1038/srep34690
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1K14-Angptl6 Tg mice exhibit a psoriasiform phenotype.
(a) K14-Angptl6 Tg mice (right panels), unlike comparably aged wild-type mice (left panels), spontaneously develop psoriasiform skin by 20 weeks of age. Squares in upper panels are magnified in corresponding lower panels. (b) HE-stained neck skin of wild-type (left) and K14-Angptl6 Tg (right) mice at 20 weeks of age. Arrows indicate epidermal thickening with elongated rete ridges. Dotted boxes are magnified in Supplementary Fig. S1b. Scale bar: 100 μm. (c) CK14 (early keratinocyte marker), CD68 (macrophage marker) and CD31 (endothelial cell marker) staining of neck skin of wild-type (left) and K14-Angptl6 Tg (right) mice at 20 weeks of age. Images are magnified from black-framed corresponding images in Supplementary Fig. S1c. Scale bar is 100 μm. (d) Psoriatic lesions of wild-type and K14-Angptl6 Tg mice at day 4 after tape stripping injury (upper). Lower panels show HE-stained sections of skin tissues from these mice. Images are magnified from black-framed corresponding images shown in Supplementary Fig. S1d. Scale bar: 100 μm. (e) Transepidermal water loss (TEWL) values in indicated skin tissues from wild-type and K14-Angptl6 Tg mice at 12 weeks of age (n = 6 per each group). (f) Representative immunoblotting and quantitation of ratio of p-STAT3 to total STAT3 from skin samples of wild-type and K14-Angptl6 Tg mice at 20 weeks of age. Hsc70 served as loading control. Values in wild-type mice were set to 1 (n = 4 per each group). (g) Quantitative real-time RT-PCR analysis of indicated cytokine/chemokine transcripts in ear tissues at 20 weeks of age. Values for respective WT mice were set to 1 (n = 4–5 per each group). Data are means ± SEM. *p < 0.05, **p < 0.01 between genotypes or groups.
Figure 2S100a8 and S100a9 levels increase in psoriasis-like lesions of K14-Angptl6 Tg mice.
(a) The top 30-upregulated mRNAs in psoriatic-like lesions from 20 weeks of age of K14-Angptl6 Tg relative to wild-type littermate mice. Genes shown in red were previously reported to be psoriatic-related genes11232425262728. (b) S100a8 and S100a9 transcript levels in psoriatic-like lesions of wild-type or K14-Angptl6 Tg mice at 20 weeks of age. Values for respective WT mice were set to 1 (n = 4–5 per each group). Data are means ± SEM. *p < 0.05, **p < 0.01 between genotypes. (c) Immunohistochemistry staining for S100a8 and S100a9 in neck skin of WT and K14-Angptl6 Tg mice at 20 weeks of age. Scale bar: 100 μm.
The top 30-upregulated mRNAs in psoriatic-like lesions from 20-week-old K14-Angptl6 Tg relative to wild-type littermate mice.
| Symbol | log2 (fold change) | p-value | |
|---|---|---|---|
| 1 | 9.26 | <0.001 | |
| 2 | 6.94 | <0.001 | |
| 3 | 6.87 | <0.001 | |
| 4 | 5.12 | <0.001 | |
| 5 | 4.9 | <0.001 | |
| 6 | 4.81 | <0.001 | |
| 7 | 4.81 | <0.001 | |
| 8 | 4.73 | <0.001 | |
| 9 | 4.67 | <0.001 | |
| 10 | 4.45 | <0.001 | |
| 11 | 4.32 | <0.001 | |
| 12 | 4.31 | <0.001 | |
| 13 | 4.28 | <0.001 | |
| 14 | 4.24 | <0.001 | |
| 15 | 4.15 | <0.001 | |
| 16 | 4.13 | <0.001 | |
| 17 | 4.05 | <0.001 | |
| 18 | 4.02 | <0.001 | |
| 19 | 3.99 | <0.001 | |
| 20 | 3.84 | <0.001 | |
| 21 | 3.81 | <0.001 | |
| 22 | 3.75 | <0.001 | |
| 23 | 3.62 | <0.001 | |
| 24 | 3.58 | <0.001 | |
| 25 | 3.54 | <0.001 | |
| 26 | 3.54 | <0.001 | |
| 27 | 3.54 | <0.001 | |
| 28 | 3.52 | <0.001 | |
| 29 | 3.52 | <0.005 | |
| 30 | 3.47 | <0.001 |
The 30 most significantly downregulated mRNAs in psoriatic-like lesions from 20-week-old K14-Angptl6 Tg relative to wild-type littermate mice.
| Symbol | log2 (fold change) | p-value | |
|---|---|---|---|
| 1 | −8.63 | <0.001 | |
| 2 | −5.77 | <0.005 | |
| 3 | −5.22 | <0.001 | |
| 4 | −5.08 | <0.01 | |
| 5 | −4.87 | <0.001 | |
| 6 | −4.75 | <0.001 | |
| 7 | −4.59 | <0.001 | |
| 8 | −4.34 | <0.001 | |
| 9 | −4.23 | <0.001 | |
| 10 | −4.23 | <0.001 | |
| 11 | −4.20 | <0.001 | |
| 12 | −4.09 | <0.001 | |
| 13 | −4.07 | <0.001 | |
| 14 | −4.06 | <0.001 | |
| 15 | −3.99 | <0.001 | |
| 16 | −3.99 | <0.001 | |
| 17 | −3.95 | <0.001 | |
| 18 | −3.94 | <0.001 | |
| 19 | −3.91 | <0.001 | |
| 20 | −3.91 | <0.005 | |
| 21 | −3.91 | <0.001 | |
| 22 | −3.91 | <0.001 | |
| 23 | −3.89 | <0.001 | |
| 24 | −3.86 | <0.001 | |
| 25 | −3.86 | <0.001 | |
| 26 | −3.83 | <0.001 | |
| 27 | −3.81 | <0.001 | |
| 28 | −3.81 | <0.001 | |
| 29 | −3.81 | <0.001 | |
| 30 | −3.74 | <0.001 |
Figure 3S100a9 loss in K14-Angptl6 Tg mice does not rescue psoriatic phenotypes.
(a) Neck skin of K14-Angptl6 Tg (left) and K14-Angptl6 Tg;S100a9−/− (right) mice at 20 weeks of age. Images are magnified from white-framed regions shown in Supplementary Fig. S3a. (b) HE staining and immunohistochemistry for CK14 (early keratinocyte marker), CD68 (macrophage marker) and CD31 (endothelial cell marker) in neck skin of K14-Angptl6 Tg (left) and K14-Angptl6 Tg;S100a9−/− (right) mice. Images are magnified from black-framed regions shown in Supplementary Fig. S3b. Scale bar: 100 μm. (c) Representative immunoblotting and quantitation of ratio of p-STAT3 to total STAT3 from skin samples of K14-Angptl6 Tg versus K14-Angptl6 Tg;S100a9−/− mice at 20 weeks of age. Hsc70 served as a loading control. Values from K14-Angptl6 Tg mice were set to 1 (n = 3 per each group). (d) Quantitative real-time RT-PCR analysis of cytokine/chemokine expression in ear tissues of K14-Angptl6 Tg and K14-Angptl6 Tg;S100a9−/− mice at 20 weeks of age. Values for respective K14-Angptl6 Tg mice were set to 1 (n = 8–10 per each group). Data are means ± SEM.
ANGPTL6, S100A8 and S100A9 expression in skin biopsies from psoriasis patients.
| Case No. | Age | Sex | ANGPTL6 Expression | S100A8 Expression | S100A9 Expression |
|---|---|---|---|---|---|
| 1 | 53 | M | (++) | (++) | (+) |
| 2 | 37 | F | (++) | (++) | (++) |
| 3 | 45 | M | (++) | (++) | (++) |
| 4 | 43 | M | (++) | (++) | (++) |
| 5 | 27 | M | (+) | (++) | (+) |
| 6 | 56 | M | (+) | (+) | (++) |
| 7 | 46 | M | (+) | (++) | (++) |
| 8 | 40 | M | (+) | (+) | (++) |
| 9 | 55 | M | (+) | (+) | (+) |
| 10 | 56 | M | (+) | (++) | (++) |
| 11 | 25 | F | (+) | (++) | (+) |
| 12 | 41 | M | (+) | (++) | (++) |
| 13 | 28 | F | (+) | (++) | (++) |
| 14 | 37 | F | (−) | (+) | (++) |
| 15 | 44 | F | (−) | (+) | (++) |
ANGPTL6, S100A8 and S100A9 expression in skin biopsies from healthy control subjects.
| Case No. | Age | Sex | ANGPTL6 Expression | S100A8 Expression | S100A9 Expression |
|---|---|---|---|---|---|
| 1 | 49 | F | (−) | (−) | (−) |
| 2 | 34 | F | (−) | (−) | (−) |
| 3 | 16 | F | (−) | (−) | (+) |
| 4 | 33 | F | (−) | (−) | (−) |
| 5 | 50 | F | (−) | (−) | (−) |
| 6 | 36 | F | (−) | (−) | (−) |
| 7 | 16 | F | (−) | (−) | (−) |
| 8 | 34 | M | (−) | (−) | (−) |
| 9 | 24 | M | (−) | (−) | (−) |
| 10 | 24 | M | (−) | (−) | (−) |
Figure 4ANGPTL6 expression is elevated in human psoriatic skin.
(a–c) Immunohistochemical staining of serial sections of human skin tissues with antibodies against ANGPTL6, S100A8 and S100A9. Shown are samples from two representative psoriasis patients, including (a) Patient 1 (37-year-old female (Case No. 2 in Table 3)) and (b) Patient 2 (37-year-old female (Case No.14 in Table 3)). (c) Also shown is a sample from a healthy control subject (34-year-old female (Case No. 2 in Table 4)). Magnified images of each dotted box are shown in Supplementary Fig. S5. Scale bar: 100 μm. (d) Representative confocal images from double immunofluorescence staining for AE1AE3 (keratinocyte marker; green) and ANGPTL6 (red, top row); CD68 (macrophage marker; green) and ANGPTL6 (red, second row); CD11c (dendritic cell marker; green) and ANGPTL6 (red, third row); and CD1a (Langerhans cell marker; green) and ANGPTL6 (red, bottom row) of a human psoriatic lesion (56-year-old male (Case No. 10 in Table 3)). Scale bar: 100 μm. Right column shows magnified images of boxed regions in adjacent image. Scale bar: 50 μm.